TRAIL, Fas ligand, TNF and TLR3 in cancer. (2017)

• Record Type: Book
• Further Information: Note: Olivier Micheau, editor.
• Editors: Micheau, Olivier
• Contents: Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer.- TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer.- IAPs andResistance to Death Receptors in Cancer.- Bcl-2 Proteins and TRAIL Resistance in Melanoma.- Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4.- Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy.- Atypical Immune Functions of CD95/CD95L.- TLR3 is a Death Receptor Target in Cancer Therapy.- Fas/CD95, Lipid Rafts and Cancer.- Role of Sphingolipids in Death Receptor Signalling.- Post-Translational Modifications and Death Receptor Signalling.- System Modeling of Receptor-Induced Apoptosis.
• Publisher Details: Cham : Springer
• Publication Date: 2017
• Copyright Date: 2017
• Extent: 1 online resource (317 pages)
• Subjects: 616.079; Neoplasms -- drug therapy; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factors; Receptors, Death Domain; Receptors, Tumor Necrosis Factor; Drug Resistance, Neoplasm; Antineoplastic Agents -- therapeutic use; Death receptors; Tumor necrosis factor -- Receptors; Death receptors; Tumor necrosis factor -- Receptors
• Languages: English
• ISBNs: 9783319568058
• Related ISBNs: 9783319568041
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.